专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08409607B2 Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods 有权
公开(公告)号：US08409607B2
公开(公告)日：2013-04-02
申请号：US12029425
申请日：2008-02-11
申请人： Patrick M. Hughes , Thomas C. Malone , Gerald W. De Vries , Jeffery L. Edelman , Joan-En Chang-Lin , Jane-Guo Shiah , Thierry Nivaggioli
发明人： Patrick M. Hughes , Thomas C. Malone , Gerald W. De Vries , Jeffery L. Edelman , Joan-En Chang-Lin , Jane-Guo Shiah , Thierry Nivaggioli
IPC分类号： A61F2/02
CPC分类号： A61K9/0051 , A61K9/1647 , Y10T428/2985
摘要： Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.

2. 发明授权

US08404267B2 Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods 有权
公开(公告)号：US08404267B2
公开(公告)日：2013-03-26
申请号：US12029424
申请日：2008-02-11
申请人： Patrick M. Hughes , Thomas C. Malone , Gerald W. De Vries , Jeffery L. Edelman , Joan-En Chang-Lin , Jane-Guo Shiah , Thierry Nivaggioli
发明人： Patrick M. Hughes , Thomas C. Malone , Gerald W. De Vries , Jeffery L. Edelman , Joan-En Chang-Lin , Jane-Guo Shiah , Thierry Nivaggioli
IPC分类号： A61F2/02
CPC分类号： A61K9/0051 , A61K9/1647 , Y10T428/2985
摘要： Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.

3. 发明授权

US07771742B2 Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods 有权
标题翻译：含有酪氨酸激酶抑制剂的持续释放眼内植入物及相关方法
公开(公告)号：US07771742B2
公开(公告)日：2010-08-10
申请号：US10837361
申请日：2004-04-30
申请人： Patrick M. Hughes , Thomas C. Malone , Gerald W. De Vries , Jeffrey L. Edelman , Joan-En Chang-Lin , Jane Guo Shiah , Thierry Nivaggioli
发明人： Patrick M. Hughes , Thomas C. Malone , Gerald W. De Vries , Jeffrey L. Edelman , Joan-En Chang-Lin , Jane Guo Shiah , Thierry Nivaggioli
IPC分类号： A61F2/14
CPC分类号： A61K9/0051 , A61K9/1647 , Y10T428/2985
摘要： Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
摘要翻译：生物相容性眼内植入物包括酪氨酸激酶抑制剂和生物可降解聚合物，其有效促进酪氨酸激酶抑制剂长时间释放到眼睛中。植入物的治疗剂可以与可生物降解的聚合物基质相关，例如基本上不含聚乙烯醇的基质。植入物可以放置在眼睛中以治疗或减少一种或多种眼部病症的发生。

4. 发明授权

US08512738B2 Biodegradable intravitreal tyrosine kinase implants 有权
标题翻译：可生物降解的玻璃体内酪氨酸激酶植入物
公开(公告)号：US08512738B2
公开(公告)日：2013-08-20
申请号：US11119001
申请日：2005-04-29
申请人： Jeffrey L. Edelman , Patrick M. Hughes , Thomas C. Malone , Gerald W. De Vries , Joan-En Chang-Lin , Jane Guo Shiah , Thierry Nivaggioli , Lon T. Spada , Wendy M. Blanda
发明人： Jeffrey L. Edelman , Patrick M. Hughes , Thomas C. Malone , Gerald W. De Vries , Joan-En Chang-Lin , Jane Guo Shiah , Thierry Nivaggioli , Lon T. Spada , Wendy M. Blanda
IPC分类号： A61F2/14
CPC分类号： A61K9/0051 , A61F9/0017 , A61K9/204 , A61K31/404 , A61K31/454 , A61K31/5377 , A61K47/34
摘要： Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as posterior ocular conditions.
摘要翻译：生物相容性眼内植入物包括酪氨酸激酶抑制剂和可生物降解的聚合物，其有效促进酪氨酸激酶抑制剂延长一段时间的眼睛玻璃体。植入物的治疗剂可以与可生物降解的聚合物基质相关，例如基本上不含聚乙烯醇的基质。植入物可以放置在眼睛中以治疗或减少一种或多种眼部病症如眼后病症的发生。

5. 发明申请

US20110076318A1 RETINOID-CONTAINING SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND RELATED MATTERS 审中-公开
标题翻译：包含持续发布的人造植入物及相关事项
公开(公告)号：US20110076318A1
公开(公告)日：2011-03-31
申请号：US12962427
申请日：2010-12-07
申请人： Patrick M. Hughes , Orest Olejnik , Glenn Tony Huang , Joan-En Chang-Lin , Thierry Nivaggioli , JaneGuo Shiah , Michele Boix , Christian Sarrazin
发明人： Patrick M. Hughes , Orest Olejnik , Glenn Tony Huang , Joan-En Chang-Lin , Thierry Nivaggioli , JaneGuo Shiah , Michele Boix , Christian Sarrazin
IPC分类号： A61M31/00 , A61K31/4436 , A61P27/02
CPC分类号： A61K31/07 , A61K9/0051 , A61K9/1647 , A61K31/203
摘要： Biocompatible intraocular implants include a retinoid component and a biodegradable polymer that is effective to facilitate release of the retinoid component into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy.
摘要翻译：生物相容性眼内植入物包括类视黄醇组分和可生物降解的聚合物，其有效促进类视黄醇组分长时间释放到眼睛中。植入物的治疗剂可以与可生物降解的聚合物基质相关，例如基本上不含聚乙烯醇的基质。植入物可以放置在眼睛中以治疗或减少一种或多种眼部病症的发生，例如视网膜损伤，包括青光眼和增生性玻璃体视网膜病变。

6. 发明申请

US20100056547A1 OPHTHALMIC COMPOSITIONS COMPRISING dDC 审中-公开
标题翻译：包含dDC的透明组合物
公开(公告)号：US20100056547A1
公开(公告)日：2010-03-04
申请号：US11909479
申请日：2006-03-21
申请人： Patrick M. Hughes , Rhett M. Schiffman , Harold G. Jensen , Joan-En Chang-Lin
发明人： Patrick M. Hughes , Rhett M. Schiffman , Harold G. Jensen , Joan-En Chang-Lin
IPC分类号： A61K31/495 , A61P27/02
CPC分类号： A61K9/0048 , A61K31/7068
摘要： A composition comprising dDC and a polymer, wherein the composition is an aqueous liquid with a viscosity which increases upon contact with a surface of an eye is disclosed herein.An aqueous composition comprising a therapeutically effective concentration of dDC, wherein the concentration of dDC is less than 1% is also disclosed.An eye drop comprising a therapeutically effective amount of dDC, wherein the amount of dDC is less than 300 μg is also disclosed.A method comprising administering an effective amount of dDC topically to an eye of a person suffering from viral conjunctivitis a viral infection, wherein less than 300 μL of dDC is administered to said eye is also disclosed.A kit comprising a composition and a dispenser, wherein said dispenser dispenses a drop comprising a therapeutically effective amount of dDC, wherein the amount of dDC is less than 300 μg is also disclosed.
摘要翻译：包含dDC和聚合物的组合物，其中所述组合物是具有在与眼表面接触时增加的粘度的水性液体。还公开了包含治疗有效浓度的dDC的水性组合物，其中dDC的浓度小于1％。还公开了包含治疗有效量的dDC的滴眼剂，其中dDC的量小于300μg。还公开了向有效量的dDC局部给予患有病毒性结膜炎的人的眼睛的病毒感染的方法，其中向所述眼睛施用少于300μL的dDC。一种包含组合物和分配器的试剂盒，其中所述分配器分配包含治疗有效量的dDC的液滴，其中dDC的量小于300μg也被公开。

7. 发明授权

US08637571B2 Compositions and methods for the intraocular transport of therapeutic agents 有权
标题翻译：治疗剂眼内运输的组合物和方法
公开(公告)号：US08637571B2
公开(公告)日：2014-01-28
申请号：US12730102
申请日：2010-03-23
申请人： Patrick M. Hughes , Orest Olejnik , Joan-En Chang-Lin
发明人： Patrick M. Hughes , Orest Olejnik , Joan-En Chang-Lin
IPC分类号： A61K31/201 , A61K38/04
CPC分类号： A61K31/557 , A61K9/0048 , A61K31/498 , A61K31/513 , A61K47/542 , A61K47/549 , A61K47/55 , A61K47/551 , A61K47/64
摘要： Membrane transporter-targeted therapeutic agents and methods of making and using the same.
摘要翻译：膜转运体靶向治疗剂及其制备和使用方法。

8. 发明申请

US20080181929A1 METHOD FOR DETERMINING OPTIMUM INTRAOCULAR LOCATIONS FOR DRUG DELIVERY IMPLANT 失效
标题翻译：用于确定药物递送植入物的最佳内部位置的方法
公开(公告)号：US20080181929A1
公开(公告)日：2008-07-31
申请号：US11948411
申请日：2007-11-30
申请人： Michael R. Robinson , Joan-En Chang-Lin , Devin F. Welty , Scott M. Whitcup , Patrick M. Hughes
发明人： Michael R. Robinson , Joan-En Chang-Lin , Devin F. Welty , Scott M. Whitcup , Patrick M. Hughes
IPC分类号： A61K9/00 , A61P27/02 , A61F9/00 , A61M37/00
CPC分类号： A61K39/3955 , A61F9/0017 , A61K9/0048 , A61K31/573 , A61K31/58
摘要： A method for determining the optimum location for placement of an intraocular implant containing used to treat an ocular condition, particularly implants comprised of a biodegradable polymer and a therapeutic agent for the treatment of retinal tissue.
摘要翻译：用于确定用于放置用于治疗眼部病症的眼内植入物的最佳位置的方法，特别是由可生物降解的聚合物和用于治疗视网膜组织的治疗剂组成的植入物。

9. 发明授权

US08571802B2 Method for determining optimum intraocular locations for drug delivery systems 失效
标题翻译：用于确定药物递送系统的最佳眼内位置的方法
公开(公告)号：US08571802B2
公开(公告)日：2013-10-29
申请号：US11948411
申请日：2007-11-30
申请人： Michael R. Robinson , Joan-En Chang-Lin , Devin F. Welty , Scott M. Whitcup , Patrick M. Hughes
发明人： Michael R. Robinson , Joan-En Chang-Lin , Devin F. Welty , Scott M. Whitcup , Patrick M. Hughes
IPC分类号： G01N33/50
CPC分类号： A61K39/3955 , A61F9/0017 , A61K9/0048 , A61K31/573 , A61K31/58
摘要： A method for determining the optimum location for placement of an intraocular implant containing used to treat an ocular condition, particularly implants comprised of a biodegradable polymer and a therapeutic agent for the treatment of retinal tissue.
摘要翻译：用于确定用于放置用于治疗眼部病症的眼内植入物的最佳位置的方法，特别是由可生物降解的聚合物和用于治疗视网膜组织的治疗剂组成的植入物。

10. 发明授权

US07931909B2 Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates 有权
标题翻译：使用具有增强的前清除率的α-2肾上腺素能受体化合物进行眼部治疗
公开(公告)号：US07931909B2
公开(公告)日：2011-04-26
申请号：US11416929
申请日：2006-05-02
申请人： Patrick M. Hughes , James A. Burke , Joan-En Chang-Lin
发明人： Patrick M. Hughes , James A. Burke , Joan-En Chang-Lin
IPC分类号： A61K9/00
CPC分类号： A61K9/0051 , A61K9/0048 , A61K9/1647
摘要： Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component which includes an alpha 2 adrenergic receptor agonist that is cleared from the anterior segment of an individual's eye to which the material is administered. The alpha 2 adrenergic receptor agonist may have a vitreal half-life greater than about three hours. The present materials are effective in treating an ocular condition(s) that affect the anterior segment of an eye, or the anterior and posterior segment of the eye. The materials are suitable for intravitreal or periocular administration and can provide prolonged drug delivery and therapeutic benefits to patients to which the materials have been administered. The alpha 2 adrenergic receptor agonists can be provided in liquid-containing formulations and/or bioerodible and/or non-bioerodible polymeric implants and microparticles. Methods of making and using the present materials are also described.
摘要翻译：眼科治疗材料，例如含液组合物和聚合物药物递送系统，包括治疗成分，其包括α2肾上腺素能受体激动剂，其从施用该物质的个体眼睛的前段清除。 α2肾上腺素能受体激动剂可具有大于约3小时的玻璃体半衰期。本发明的材料可有效治疗影响眼前段或眼部前段和后段的眼睛状况。这些材料适用于玻璃体内或眼周内给药，并且可以为已经施用材料的患者提供延长的药物递送和治疗益处。 α2肾上腺素能受体激动剂可以在含液制剂和/或生物可侵蚀和/或非生物可侵蚀的聚合物植入物和微粒中提供。还描述了制备和使用本发明材料的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式